RU2016151761A - Очищенные композиции белков ivig и kh для модулирования лимфоцитов и лечения вируса гепатита b - Google Patents

Очищенные композиции белков ivig и kh для модулирования лимфоцитов и лечения вируса гепатита b Download PDF

Info

Publication number
RU2016151761A
RU2016151761A RU2016151761A RU2016151761A RU2016151761A RU 2016151761 A RU2016151761 A RU 2016151761A RU 2016151761 A RU2016151761 A RU 2016151761A RU 2016151761 A RU2016151761 A RU 2016151761A RU 2016151761 A RU2016151761 A RU 2016151761A
Authority
RU
Russia
Prior art keywords
seq
amino acid
acid sequence
substantially pure
protein
Prior art date
Application number
RU2016151761A
Other languages
English (en)
Russian (ru)
Other versions
RU2016151761A3 (https=
Inventor
Кью ХОАНГ
Original Assignee
Рэар Энтибоди Энтиджен Сеплай, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54699755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2016151761(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Рэар Энтибоди Энтиджен Сеплай, Инк. filed Critical Рэар Энтибоди Энтиджен Сеплай, Инк.
Publication of RU2016151761A publication Critical patent/RU2016151761A/ru
Publication of RU2016151761A3 publication Critical patent/RU2016151761A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2016151761A 2014-05-28 2015-05-28 Очищенные композиции белков ivig и kh для модулирования лимфоцитов и лечения вируса гепатита b RU2016151761A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462003664P 2014-05-28 2014-05-28
US62/003,664 2014-05-28
PCT/US2015/032807 WO2015184050A1 (en) 2014-05-28 2015-05-28 Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus

Publications (2)

Publication Number Publication Date
RU2016151761A true RU2016151761A (ru) 2018-07-03
RU2016151761A3 RU2016151761A3 (https=) 2018-12-26

Family

ID=54699755

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016151761A RU2016151761A (ru) 2014-05-28 2015-05-28 Очищенные композиции белков ivig и kh для модулирования лимфоцитов и лечения вируса гепатита b

Country Status (10)

Country Link
EP (1) EP3148574B1 (https=)
JP (1) JP2017525752A (https=)
CN (1) CN107106664A (https=)
AU (1) AU2015266997A1 (https=)
BR (1) BR112016027818A2 (https=)
CA (1) CA2949994A1 (https=)
ES (1) ES2878043T3 (https=)
MX (1) MX2016015574A (https=)
RU (1) RU2016151761A (https=)
WO (1) WO2015184050A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184050A1 (en) 2014-05-28 2015-12-03 Rare Antibody Antigen Supply, Inc. Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus
US20160289300A1 (en) * 2015-04-02 2016-10-06 Kieu Hoang Method of manufacturing intravenous immunoglobulin from fraction iii
CN107921080A (zh) * 2015-04-02 2018-04-17 K·黄 由组分iii制造并纯化出用于静脉注射的凝血酶原复合物浓缩剂的方法以及治疗和预防具有抑制剂的a型血友病或感染了hiv‑1和hiv‑2的b型血友病患者的方法
CN118903378A (zh) * 2024-03-19 2024-11-08 北京达尔文细胞生物科技有限公司 一种蛋白聚合物在治疗渐冻症中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
GB0315248D0 (en) * 2003-06-30 2003-08-06 Hoffmann La Roche HCV regulated protein expression
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CA2639003A1 (en) 2008-08-20 2010-02-20 Canadian Blood Services Inhibition of fc.gamma.r-mediated phagocytosis with reduced immunoglobulin preparations
US10233228B2 (en) * 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
WO2011143637A1 (en) * 2010-05-14 2011-11-17 The Regents Of The University Of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
WO2015184050A1 (en) 2014-05-28 2015-12-03 Rare Antibody Antigen Supply, Inc. Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus
TW201335181A (zh) 2012-01-31 2013-09-01 Kieu Hoang 55種新發現的蛋白質之序列及其應用

Also Published As

Publication number Publication date
ES2878043T3 (es) 2021-11-18
EP3148574A4 (en) 2017-04-05
MX2016015574A (es) 2018-05-28
CN107106664A (zh) 2017-08-29
CA2949994A1 (en) 2015-12-03
WO2015184050A1 (en) 2015-12-03
EP3148574B1 (en) 2021-04-14
JP2017525752A (ja) 2017-09-07
AU2015266997A1 (en) 2016-12-08
BR112016027818A2 (pt) 2017-10-24
RU2016151761A3 (https=) 2018-12-26
EP3148574A1 (en) 2017-04-05

Similar Documents

Publication Publication Date Title
JP6067560B2 (ja) 無血清培養及び浮遊培養に適応されたmdck細胞株及び前記細胞を使用してワクチン用ウイルスを製造する方法
CA2796409A1 (en) Process for preparing an immunoglobulin composition
JP3313117B2 (ja) ウイルス粒子の効率の高い生産および単離
RU2016151761A (ru) Очищенные композиции белков ivig и kh для модулирования лимфоцитов и лечения вируса гепатита b
JP2013530950A5 (https=)
RU2013128866A (ru) Иммуногенные пептиды для применения в профилактике и/или лечении инфекционных заболеваний, аутоиммунных заболеваний, иммунных ответов на аллогенные факторы, аллергических заболеваний, опухолей, отторжения трансплантата и иммунных ответов против вирусных векторов, используемых для генной терапии или генной вакцинации
JP6474798B2 (ja) 方法
JP2011524887A5 (https=)
US10633432B2 (en) VC-CAR molecule and use thereof in removing HIV-1 infected cells
CN103554253A (zh) 一种静注人免疫球蛋白的制备方法
EP4628095A1 (en) Fusion protein and granulated antigen comprising same
JP2017525752A5 (https=)
DE19504211A1 (de) Entfernen von Viren durch Ultrafiltration aus Proteinlösungen
CN102816230A (zh) 人血白蛋白的制备方法
CN110616188B (zh) 一种通用型car-t细胞及其制备方法和应用
CN107847541A (zh) 克隆并进一步纯化以制备重组静脉注射免疫球蛋白的方法
RU2493872C1 (ru) Способ очистки вируса гриппа
JP2023526738A (ja) タンパク質の単純化した高効率単離のための組成物および方法
DE68913932T2 (de) Arzneimittel für die Behandlung oder die Verhütung von Infektionen mit HIV durch Immunisierung, und Verfahren zur Herstellung.
RU2018132668A (ru) Способ получения вирусбезопасного раствора иммуноглобулина g человека для внутримышечного введения
CN102344484A (zh) 提取光合膜蛋白(光系统ⅰ)的方法
RU2067767C1 (ru) Способ получения субъединичной генноинженерной вакцины против гепатита в
CN107921079A (zh) 由组分iii制造静脉注射免疫球蛋白的方法
AR129192A1 (es) Fraccionamiento de plasma mediante un agrupamiento de cohn concentrado como materia prima
CN117838734A (zh) 感染性心内膜炎病原菌来源的外膜囊泡在作为诱导细胞空泡化的制剂中的应用

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200218